These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15694012)

  • 1. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 3. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 4. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
    Saijo N
    Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated data from the Iressa survival in lung cancer trial.
    Tyagi P
    Clin Lung Cancer; 2005 May; 6(6):340-2. PubMed ID: 15943893
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
    Madelaine J; Cadranel J; Zalcman G
    Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
    [No Abstract]   [Full Text] [Related]  

  • 10. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
    Ranson M; Thatcher N
    Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
    Manegold C
    Adv Exp Med Biol; 2003; 532():247-52. PubMed ID: 12908563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
    Shimizu J; Horio Y; Mitsudomi T
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR pharmacogenomics: the story continues to mutate and evolve.
    Desai AA; Ratain MJ
    Am J Pharmacogenomics; 2005; 5(2):137-9. PubMed ID: 15813677
    [No Abstract]   [Full Text] [Related]  

  • 15. The miracle of Iressa.
    Chabner BA
    Oncologist; 2004; 9(3):245-6. PubMed ID: 15169979
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
    Dancey JE
    Cancer Cell; 2004 May; 5(5):411-5. PubMed ID: 15144948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
    Sridhar SS; Seymour L; Shepherd FA
    Lancet Oncol; 2003 Jul; 4(7):397-406. PubMed ID: 12850190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
    Hishida T; Nagai K; Mitsudomi T; Yokoi K; Kondo H; Horinouchi H; Akiyama H; Nagayasu T; Tsuboi M;
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):e69-71. PubMed ID: 20674944
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.